Top 5 Drug Type | Count |
---|---|
Small molecule drug | 8 |
Unknown | 2 |
Chemical drugs | 2 |
Target |
Mechanism EGFR antagonists [+2] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. US |
First Approval Date15 May 2020 |
Target- |
Mechanism- |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePhase 3 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism CSF-1R antagonists |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhasePhase 3 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date01 May 2024 |
Sponsor / Collaborator |
Start Date13 Dec 2023 |
Sponsor / Collaborator |
Start Date28 Sep 2023 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
Ripretinib ( EGFR x PDGFRα x c-Kit ) | Gastrointestinal Stromal Tumors More | Approved |
Vimseltinib ( CSF-1R ) | Pigmented Villonodular Synovitis More | Phase 3 |
Vinseltinib | Giant Cell Tumor of Tendon Sheath More | Phase 2 Clinical |
DCC-3116 ( ULK1 x ULK2 ) | Gastrointestinal Stromal Tumors More | Phase 2 Clinical |
Rebastinib Tosylate ( Bcr-Abl T315I x Tie-2 ) | Chronic Lymphocytic Leukemia More | Phase 2 |